Raymond James Trust N.A. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 3.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 294,072 shares of the company’s stock after buying an additional 9,613 shares during the quarter. Merck & Co., Inc. makes up approximately 1.1% of Raymond James Trust N.A.’s portfolio, making the stock its 17th largest holding. Raymond James Trust N.A.’s holdings in Merck & Co., Inc. were worth $24,393,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Ceredex Value Advisors LLC bought a new position in Merck & Co., Inc. during the second quarter valued at about $102,394,000. Personal Capital Advisors Corp boosted its position in Merck & Co., Inc. by 11.9% during the second quarter. Personal Capital Advisors Corp now owns 75,736 shares of the company’s stock worth $5,857,000 after purchasing an additional 8,048 shares during the period. Capital Asset Advisory Services LLC boosted its position in Merck & Co., Inc. by 15.2% during the first quarter. Capital Asset Advisory Services LLC now owns 8,079 shares of the company’s stock worth $629,000 after purchasing an additional 1,066 shares during the period. Janney Montgomery Scott LLC boosted its position in Merck & Co., Inc. by 18.1% during the second quarter. Janney Montgomery Scott LLC now owns 1,372,241 shares of the company’s stock worth $106,115,000 after purchasing an additional 209,990 shares during the period. Finally, First PREMIER Bank boosted its position in Merck & Co., Inc. by 5.2% during the second quarter. First PREMIER Bank now owns 27,864 shares of the company’s stock worth $2,154,000 after purchasing an additional 1,389 shares during the period. Institutional investors own 73.18% of the company’s stock.
A number of equities analysts have weighed in on MRK shares. SVB Leerink increased their target price on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Berenberg Bank started coverage on shares of Merck & Co., Inc. in a research report on Tuesday, September 29th. They set a “hold” rating and a $88.00 target price for the company. Morgan Stanley reiterated a “buy” rating and set a $89.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 23rd. ValuEngine lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Thursday, October 1st. Finally, Goldman Sachs Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their target price for the stock from $91.00 to $105.00 in a research report on Monday, August 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $95.08.
In related news, insider Sanat Chattopadhyay sold 10,380 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $83.01, for a total value of $861,643.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Robert M. Davis sold 251,273 shares of Merck & Co., Inc. stock in a transaction on Monday, October 5th. The shares were sold at an average price of $81.03, for a total transaction of $20,360,651.19. Following the completion of the sale, the chief financial officer now owns 422,329 shares in the company, valued at approximately $34,221,318.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 280,529 shares of company stock worth $22,761,633. 0.28% of the stock is currently owned by company insiders.
MRK stock opened at $79.83 on Friday. The company has a market capitalization of $201.91 billion, a PE ratio of 19.47, a price-to-earnings-growth ratio of 2.10 and a beta of 0.43. Merck & Co., Inc. has a one year low of $65.25 and a one year high of $92.64. The company’s 50 day moving average price is $83.27 and its two-hundred day moving average price is $80.42. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.32.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Friday, July 31st. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The firm had revenue of $10.87 billion for the quarter, compared to the consensus estimate of $10.52 billion. During the same period last year, the firm posted $1.30 earnings per share. The business’s revenue was down 7.6% compared to the same quarter last year. On average, research analysts predict that Merck & Co., Inc. will post 5.68 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.61 dividend. This represents a $2.44 annualized dividend and a yield of 3.06%. The ex-dividend date was Monday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.01%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Recommended Story: Example of operating income, EBIT and EBITDA
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.